Gabriel Ribeiro dos Santos
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Gabriel Ribeiro dos Santos has a total of 137 co-authors. Here are the top co-authors by number of shared publications:
- Henrik Salje
Department of Genetics, University of Cambridge, Cambridge, United Kingdom
14 shared publications Danny Scarponi
Coalition for Epidemic Preparedness Innovations, London, UK
6 shared publicationsChristinah Mukandavire
Coalition for Epidemic Preparedness Innovations, London, UK
5 shared publications- Simon Cauchemez
Mathematical Modelling of Infectious Diseases Unit, Institut Pasteur, Université Paris Cité, INSERM U1332, CNRS UMR 2000, Paris, France
5 shared publications - Derek A. T. Cummings
Departments of Epidemiology and Biomedical Engineering, Johns Hopkins University, 615 N Wolfe St, Baltimore, MD 21205, United States
4 shared publications Arminder Deol
Coalition for Epidemic Preparedness Innovations (CEPI)
3 shared publications
Latest Publications
- Open Access
- 10 November 2025
- Published by Springer Nature in Nature Medicine
- Vol. 31 (12) , 4312
Author Correction: Global burden of chikungunya virus infections and the potential benefit of vaccination campaigns
- 10 November 2025
- Published by Springer Nature in Nature Medicine
- Vol. 31 (12) , 4312
Open AccessAuthor Correction: Global burden of chikungunya virus infections and the potential benefit of vaccination campaigns
- Open Access
The epidemiology of chikungunya virus in Brazil and potential impact of vaccines
The first chikungunya virus (CHIKV) vaccine is now licensed in Brazil, the country that reports most cases globally, however, the optimal use of the vaccine remains unclear due to a poor understanding of CHIKV epidemiology and population immunity. We quantified the annual CHIKV infection and disease burden since 2014 in each of the 27 Federal Units of Brazil using a mathematical model that integrated serological surveys (N=12), confirmed chikungunya cases (N=488,234) and chikungunya deaths (N=1,719) reported between January 2014 and September 2024. Using this base, we estimated the potential impact of a vaccine over the period 2025-2029 had the population been vaccinated before the 2025 season, evaluating different rollout strategies. We found that 18.3% (95%CrI: 16.5-20.3) of the population has been infected since 2014, with the highest risk concentrated in the Northeast and Southeast. Overall, 1.13% (95%CrI: 1.07-1.19) of infections were detected by surveillance systems, with an increasing probability of symptoms with age and greater risk of symptoms in females. Vaccinating 40% of the population aged >12y (73 million doses), and assuming a vaccine efficacy of 70% against infection and 95% against disease, would avert up to 1.6 million (95%CrI: 0.5-3) cases and 198 (95%CrI: 61-359) deaths over the next five years. Despite widespread circulation, most of the country remains vulnerable to infection. CHIKV vaccination has the potential to substantially reduce disease burden.
Open AccessThe epidemiology of chikungunya virus in Brazil and potential impact of vaccines
The first chikungunya virus (CHIKV) vaccine is now licensed in Brazil, the country that reports most cases globally, however, the optimal use of the vaccine remains unclear due to a poor understanding of CHIKV epidemiology and population immunity. We quantified the annual CHIKV infection and disease burden since 2014 in each of the 27 Federal Units of Brazil using a mathematical model that integrated serological surveys (N=12), confirmed chikungunya cases (N=488,234) and chikungunya deaths (N=1,719) reported between January 2014 and September 2024. Using this base, we estimated the potential impact of a vaccine over the period 2025-2029 had the population been vaccinated before the 2025 season, evaluating different rollout strategies. We found that 18.3% (95%CrI: 16.5-20.3) of the population has been infected since 2014, with the highest risk concentrated in the Northeast and Southeast. Overall, 1.13% (95%CrI: 1.07-1.19) of infections were detected by surveillance systems, with an increasing probability of symptoms with age and greater risk of symptoms in females. Vaccinating 40% of the population aged >12y (73 million doses), and assuming a vaccine efficacy of 70% against infection and 95% against disease, would avert up to 1.6 million (95%CrI: 0.5-3) cases and 198 (95%CrI: 61-359) deaths over the next five years. Despite widespread circulation, most of the country remains vulnerable to infection. CHIKV vaccination has the potential to substantially reduce disease burden.
- Open Access
National burden and optimal vaccine policy for Japanese encephalitis virus in Bangladesh
Background Bangladesh first reported Japanese encephalitis virus (JEV) in 1977 and has seen regular cases since, however, no JEV vaccination program currently exists. A barrier to the use of JEV vaccines has been a limited understanding of the underlying burden. Methods We conducted a nationally representative serological community study in 70 communities in individuals of all ages (N=2,938, October 2015-January 2016). Serum samples were tested for IgG antibodies against JEV. We developed spatially explicit serocatalytic models to estimate the underlying force of infection across the country. We then used mathematical models to estimate the annual JE disease burden currently and under different vaccination strategies. Findings The overall JEV seroprevalence in Bangladesh was 3.4% (95%CI: 2.8–4.1, range 0–28% across communities). The annual probability of infection was 0.005 (95%CI: 0.003–0.009), with risk greatest near border regions. We estimated that annually there are 157 clinical cases (95%CI: 89-253) and 31 deaths (95%CI: 18-52). A vaccination strategy in the 10 most affected districts in 60% of 1–15 year olds would require 5 million doses and avert 1 case per 100,000 doses over five years compared to 35 million doses and 0.5 cases averted for a nationwide campaign. No vaccination scenario was cost-effective under a willingness-to-pay of three-times gross domestic product. Interpretation A spatially targeted vaccine campaign would be most effective in reducing JEV burden, however, would still not meet standard cost effectiveness targets. Funding CDC
Open AccessNational burden and optimal vaccine policy for Japanese encephalitis virus in Bangladesh
Background Bangladesh first reported Japanese encephalitis virus (JEV) in 1977 and has seen regular cases since, however, no JEV vaccination program currently exists. A barrier to the use of JEV vaccines has been a limited understanding of the underlying burden. Methods We conducted a nationally representative serological community study in 70 communities in individuals of all ages (N=2,938, October 2015-January 2016). Serum samples were tested for IgG antibodies against JEV. We developed spatially explicit serocatalytic models to estimate the underlying force of infection across the country. We then used mathematical models to estimate the annual JE disease burden currently and under different vaccination strategies. Findings The overall JEV seroprevalence in Bangladesh was 3.4% (95%CI: 2.8–4.1, range 0–28% across communities). The annual probability of infection was 0.005 (95%CI: 0.003–0.009), with risk greatest near border regions. We estimated that annually there are 157 clinical cases (95%CI: 89-253) and 31 deaths (95%CI: 18-52). A vaccination strategy in the 10 most affected districts in 60% of 1–15 year olds would require 5 million doses and avert 1 case per 100,000 doses over five years compared to 35 million doses and 0.5 cases averted for a nationwide campaign. No vaccination scenario was cost-effective under a willingness-to-pay of three-times gross domestic product. Interpretation A spatially targeted vaccine campaign would be most effective in reducing JEV burden, however, would still not meet standard cost effectiveness targets. Funding CDC
- Top Cited PapersOpen Access
- 10 June 2025
- Published by Springer Nature in Nature Medicine
- Vol. 31 (7) , 2342-2349
Global burden of chikungunya virus infections and the potential benefit of vaccination campaigns
The first vaccine against chikungunya virus (CHIKV) has now been licensed; however, due to a limited knowledge of the underlying global burden, its potential to reduce disease burden remains unknown. We used data from seroprevalence studies, observed cases and mosquito distributions to quantify the underlying CHIKV burden in 180 countries and territories, and we explored the potential impact of vaccination campaigns. We estimate that 104 countries have experienced CHIKV transmission, covering 2.8 billion people, and that, in epidemic settings, the mean duration between outbreaks is 6.2 years, with 8.4% of the susceptible population infected per outbreak. Globally, there are 35 million annual infections, mainly in Southeast Asia, Africa and the Americas. Assuming a vaccine efficacy against disease of 70% and a protection against infection of 40%, vaccinating 50% of individuals over 12 years of age in places and times where the virus circulates would avert 4,436 infections, 0.34 deaths and 37 disability-adjusted life years per 100,000 doses used. These findings highlight the global burden of chikungunya and the potential of CHIKV vaccination campaigns.
- 10 June 2025
- Published by Springer Nature in Nature Medicine
- Vol. 31 (7) , 2342-2349
Top Cited PapersOpen AccessGlobal burden of chikungunya virus infections and the potential benefit of vaccination campaigns
The first vaccine against chikungunya virus (CHIKV) has now been licensed; however, due to a limited knowledge of the underlying global burden, its potential to reduce disease burden remains unknown. We used data from seroprevalence studies, observed cases and mosquito distributions to quantify the underlying CHIKV burden in 180 countries and territories, and we explored the potential impact of vaccination campaigns. We estimate that 104 countries have experienced CHIKV transmission, covering 2.8 billion people, and that, in epidemic settings, the mean duration between outbreaks is 6.2 years, with 8.4% of the susceptible population infected per outbreak. Globally, there are 35 million annual infections, mainly in Southeast Asia, Africa and the Americas. Assuming a vaccine efficacy against disease of 70% and a protection against infection of 40%, vaccinating 50% of individuals over 12 years of age in places and times where the virus circulates would avert 4,436 infections, 0.34 deaths and 37 disability-adjusted life years per 100,000 doses used. These findings highlight the global burden of chikungunya and the potential of CHIKV vaccination campaigns.
- Open Access
- 1 May 2025
- Published by Springer Nature in Nature Medicine
- Vol. 31 (7) , 2335-2341
Modeling the impact of vaccine campaigns on the epidemic transmission dynamics of chikungunya virus outbreaks
A licensed chikungunya vaccine now exists; however, it remains unclear whether it could be deployed during outbreaks to reduce the health burden. We used an epidemic in Paraguay as a case study. We conducted a seroprevalence study and used models to reconstruct epidemic transmission dynamics, providing a framework to assess the theoretical impact of a vaccine had it been available. We estimated that 33.0% (95% confidence interval (CI) 30.1–36.0%) of the population became infected during the outbreak. Of these individuals, 6.3% (95% CI 5.8–6.9%) were detected by the surveillance system, with a mean infection fatality ratio of 0.013% (95% CI 0.012–0.014%). A disease-blocking vaccine with 75% efficacy deployed in 40% of individuals aged ≥12 years over a 3-month period would have prevented 34,200 (95% CI 30,900–38,000) cases, representing 23% of all cases, and 73 (95% CI 66–81) deaths. If the vaccine also leads to infection blocking, 88% of cases would have been averted. These findings suggest that the vaccine is an important new tool to control outbreaks.
- 1 May 2025
- Published by Springer Nature in Nature Medicine
- Vol. 31 (7) , 2335-2341
Open AccessModeling the impact of vaccine campaigns on the epidemic transmission dynamics of chikungunya virus outbreaks
A licensed chikungunya vaccine now exists; however, it remains unclear whether it could be deployed during outbreaks to reduce the health burden. We used an epidemic in Paraguay as a case study. We conducted a seroprevalence study and used models to reconstruct epidemic transmission dynamics, providing a framework to assess the theoretical impact of a vaccine had it been available. We estimated that 33.0% (95% confidence interval (CI) 30.1–36.0%) of the population became infected during the outbreak. Of these individuals, 6.3% (95% CI 5.8–6.9%) were detected by the surveillance system, with a mean infection fatality ratio of 0.013% (95% CI 0.012–0.014%). A disease-blocking vaccine with 75% efficacy deployed in 40% of individuals aged ≥12 years over a 3-month period would have prevented 34,200 (95% CI 30,900–38,000) cases, representing 23% of all cases, and 73 (95% CI 66–81) deaths. If the vaccine also leads to infection blocking, 88% of cases would have been averted. These findings suggest that the vaccine is an important new tool to control outbreaks.
- 24 March 2025
- Published by Springer Nature in Nature Human Behaviour
- Vol. 9 (7) , 1309-1312
Improving mobility data for infectious disease research
- 24 March 2025
- Published by Springer Nature in Nature Human Behaviour
- Vol. 9 (7) , 1309-1312
Improving mobility data for infectious disease research
- Open Access
- 31 December 2024
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 122 (1)
Reconciling heterogeneous dengue virus infection risk estimates from different study designs
Uncovering rates at which susceptible individuals become infected with a pathogen, i.e., the force of infection (FOI), is essential for assessing transmission risk and reconstructing distribution of immunity in a population. For dengue, reconstructing exposure and susceptibility statuses from the measured FOI is of particular significance as prior exposure is a strong risk factor for severe disease. FOI can be measured via many study designs. Longitudinal serology is considered gold standard measurements, as they directly track the transition of seronegative individuals to seropositive due to incident infections (seroincidence). Cross-sectional serology can provide estimates of FOI by contrasting seroprevalence across ages. Age of reported cases can also be used to infer FOI. Agreement of these measurements, however, has not been assessed. Using 26 y of data from cohort studies and hospital-attended cases from Kamphaeng Phet province, Thailand, we found FOI estimates from the three sources to be highly inconsistent. Annual FOI estimates from seroincidence were 1.75 to 4.05 times higher than case-derived FOI. Seroprevalence-derived was moderately correlated with case-derived FOI (correlation coefficient = 0.47) with slightly lower estimates. Through extensive simulations and theoretical analysis, we show that incongruences between methods can result from failing to account for dengue antibody kinetics, assay noise, and heterogeneity in FOI across ages. Extending standard inference models to include these processes reconciled the FOI and susceptibility estimates. Our results highlight the importance of comparing inferences across multiple data types to uncover additional insights not attainable through a single data type/analysis.
- 31 December 2024
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 122 (1)
Open AccessReconciling heterogeneous dengue virus infection risk estimates from different study designs
Uncovering rates at which susceptible individuals become infected with a pathogen, i.e., the force of infection (FOI), is essential for assessing transmission risk and reconstructing distribution of immunity in a population. For dengue, reconstructing exposure and susceptibility statuses from the measured FOI is of particular significance as prior exposure is a strong risk factor for severe disease. FOI can be measured via many study designs. Longitudinal serology is considered gold standard measurements, as they directly track the transition of seronegative individuals to seropositive due to incident infections (seroincidence). Cross-sectional serology can provide estimates of FOI by contrasting seroprevalence across ages. Age of reported cases can also be used to infer FOI. Agreement of these measurements, however, has not been assessed. Using 26 y of data from cohort studies and hospital-attended cases from Kamphaeng Phet province, Thailand, we found FOI estimates from the three sources to be highly inconsistent. Annual FOI estimates from seroincidence were 1.75 to 4.05 times higher than case-derived FOI. Seroprevalence-derived was moderately correlated with case-derived FOI (correlation coefficient = 0.47) with slightly lower estimates. Through extensive simulations and theoretical analysis, we show that incongruences between methods can result from failing to account for dengue antibody kinetics, assay noise, and heterogeneity in FOI across ages. Extending standard inference models to include these processes reconciled the FOI and susceptibility estimates. Our results highlight the importance of comparing inferences across multiple data types to uncover additional insights not attainable through a single data type/analysis.
- Open Access
Characterising the 2023 chikungunya outbreak in Paraguay and the potential impact of a vaccine campaign
There now exists a licensed chikungunya vaccine, however, it remains unclear if it could be deployed during outbreaks to reduce the health burden. We used an epidemic in Paraguay as a case study. We conducted a seroprevalence study and used models to reconstruct epidemic transmission dynamics, providing a framework to assess the theoretical impact of a vaccine had it been available. We estimated 33.0% (95% CI: 30.1-36.0) of the population became infected during the outbreak, 6.3% (95%CI: 5.8-6.9) of which were detected by the surveillance system, with a mean infection fatality ratio of 0.013 % (95%CI: 0.012-0.014). A disease-blocking vaccine with 75% efficacy deployed in 40% of > 12-year-olds over a three-month period would have prevented 34,200 (95% CI: 30,900-38,000) cases, representing 23% of cases, and 73 (95%CI: 66-81) deaths. If the vaccine also leads to infection blocking, 88% of cases would have been averted. These findings suggest the vaccine is an important new tool to control outbreaks.
Open AccessCharacterising the 2023 chikungunya outbreak in Paraguay and the potential impact of a vaccine campaign
There now exists a licensed chikungunya vaccine, however, it remains unclear if it could be deployed during outbreaks to reduce the health burden. We used an epidemic in Paraguay as a case study. We conducted a seroprevalence study and used models to reconstruct epidemic transmission dynamics, providing a framework to assess the theoretical impact of a vaccine had it been available. We estimated 33.0% (95% CI: 30.1-36.0) of the population became infected during the outbreak, 6.3% (95%CI: 5.8-6.9) of which were detected by the surveillance system, with a mean infection fatality ratio of 0.013 % (95%CI: 0.012-0.014). A disease-blocking vaccine with 75% efficacy deployed in 40% of > 12-year-olds over a three-month period would have prevented 34,200 (95% CI: 30,900-38,000) cases, representing 23% of cases, and 73 (95%CI: 66-81) deaths. If the vaccine also leads to infection blocking, 88% of cases would have been averted. These findings suggest the vaccine is an important new tool to control outbreaks.
- Open Access
The global burden of chikungunya virus and the potential benefit of vaccines
The first chikungunya virus (CHIKV) vaccine has now been licensed, however, its potential to reduce disease burden remains unknown due to a poor knowledge of the underlying global burden. We use data from seroprevalence studies, observed cases and mosquito distributions to quantify the underlying burden in 190 countries and territories, and explore the potential impact of the vaccine. We estimate that 104 countries have experienced transmission, covering 2.8 billion individuals and that in epidemic settings, the mean duration between outbreaks is 6.2 years, with 8.4% of the susceptible population infected per outbreak. Globally there are 33.7 million annual infections, driven by countries in Southeast Asia, Africa and the Americas. Assuming a vaccine efficacy against disease of 70% a protection against infection of 40%, vaccinating 50% of individuals over 12 years old in places and times where the virus circulates would avert 3,718 infections, 2.8 deaths and 158 DALYs per 100,000 doses used. These findings highlight the global burden and the significant potential of the vaccine.
Open AccessThe global burden of chikungunya virus and the potential benefit of vaccines
The first chikungunya virus (CHIKV) vaccine has now been licensed, however, its potential to reduce disease burden remains unknown due to a poor knowledge of the underlying global burden. We use data from seroprevalence studies, observed cases and mosquito distributions to quantify the underlying burden in 190 countries and territories, and explore the potential impact of the vaccine. We estimate that 104 countries have experienced transmission, covering 2.8 billion individuals and that in epidemic settings, the mean duration between outbreaks is 6.2 years, with 8.4% of the susceptible population infected per outbreak. Globally there are 33.7 million annual infections, driven by countries in Southeast Asia, Africa and the Americas. Assuming a vaccine efficacy against disease of 70% a protection against infection of 40%, vaccinating 50% of individuals over 12 years old in places and times where the virus circulates would avert 3,718 infections, 2.8 deaths and 158 DALYs per 100,000 doses used. These findings highlight the global burden and the significant potential of the vaccine.
- Open Access
- 29 June 2024
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 230 (5) , e1031-e1038
Results of a Nationally Representative Seroprevalence Survey of Chikungunya Virus in Bangladesh
There is an increasing global burden from chikungunya virus (CHIKV). Bangladesh reported a major epidemic in 2017, however, it was unclear if there had been prior widespread transmission. We conducted a nationally representative seroprevalence survey in 70 randomly selected communities immediately prior to the epidemic. We found 69/2,938 (2.4%) of sampled individuals were seropositive to CHIKV. Being seropositive to dengue virus (aOR 3.13 [95% CIs: 1.86-5.27]), male sex (aOR 0.59 [95% CIs: 0.36-0.99]), and community presence of Aedes aegypti mosquitoes (aOR: 1.80, 95% CI: 1.05–3.07) were significantly associated with CHIKV seropositivity. Using a spatial prediction model, we estimated that across the country, 4.99 (95% CI: 4.89 - 5.08) million people had been previously infected. These findings highlight high population susceptibility prior to the major outbreak and that previous outbreaks must have been spatially isolated.
- 29 June 2024
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 230 (5) , e1031-e1038
Open AccessResults of a Nationally Representative Seroprevalence Survey of Chikungunya Virus in Bangladesh
There is an increasing global burden from chikungunya virus (CHIKV). Bangladesh reported a major epidemic in 2017, however, it was unclear if there had been prior widespread transmission. We conducted a nationally representative seroprevalence survey in 70 randomly selected communities immediately prior to the epidemic. We found 69/2,938 (2.4%) of sampled individuals were seropositive to CHIKV. Being seropositive to dengue virus (aOR 3.13 [95% CIs: 1.86-5.27]), male sex (aOR 0.59 [95% CIs: 0.36-0.99]), and community presence of Aedes aegypti mosquitoes (aOR: 1.80, 95% CI: 1.05–3.07) were significantly associated with CHIKV seropositivity. Using a spatial prediction model, we estimated that across the country, 4.99 (95% CI: 4.89 - 5.08) million people had been previously infected. These findings highlight high population susceptibility prior to the major outbreak and that previous outbreaks must have been spatially isolated.